A Must S.E.A. Event: Understanding the Burden and Unmet Needs of Patients with Uncontrolled Severe Asthma and Associated Co-morbidities
Webinar recorded May 26, 2022
Sponsored by GSK
Approximately 3%–10% of patients with asthma worldwide have severe asthma (SA) and SA includes several specific phenotypes and endotypes that differ in their clinical presentation, molecular mechanisms, and response to treatment. Severe eosinophilic asthma (SEA) is a phenotype of severe asthma and a majority of SA patients may have evidence of an eosinophilic phenotype. Severe asthma is more frequently associated with comorbid diseases, as compared to less severe asthma, and includes diseases such has Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
The clinical and economic disease burden on patients with SEA is significant, resulting in elevated health care costs and resource utilization.
This program will review:
- Definitions and guideline recommendations for management of severe asthma
- The role of eosinophils in SEA and their link to patient outcomes, including exacerbations
- Comorbidities associated SEA with a focus on CRSwNP
At the end of the program, attendees should be able to:
- Understand the burden of SEA and how to manage patients based on treatment guidelines
- Discuss the importance of phenotyping patients, and the role of eosinophils and their link to patient outcomes, including exacerbations
- Discuss the risks of short-term and chronic use of oral corticosteroids in the management of the SEA patient
- Recognize and understand the impact of comorbidities associated with SEA
- Brian Modena, MD, MSc
Modena Allergy & Asthma Inc.
Principal Investigator, The Asthma Genome Project
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.